BICYCLE THERAPEUTICS PLC
BICYCLE THERAPEUTICS PLC (BCYC): 18 pipeline candidates · ~26 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
26.3 months
D/E 0.18 · 0% dilution
Lead: Phase 2
18 candidates
N/A
0 buys · 24 sells (180d)
A transparent, data-derived signal for BICYCLE THERAPEUTICS PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$282.7M
Cash
$560.1M
Quarterly Burn
$65.9M
Runway
26.3 mo
Revenue
$887K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| bt1702 | Preclinical |
| BT1718 | Phase 1 |
| BT5528 | Phase 2 |
| BT7401 | Phase 1 |
| BT7455 | Preclinical |
| BT7480 | Phase 1 |
| BT8009 | Phase 2 |
| EphA2 (BRC) | Phase 1 |
| ion826 | Phase 1 |
| MT1-MMP | Preclinical |
Showing 10 of 18 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$131.4M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 10,885,357 | $50.5M |
| fcpm iii services b.v. | 3,468,430 | $16.1M |
| armistice capital, llc | 3,398,000 | $15.8M |
| principal financial group inc | 1,174,625 | $5.5M |
| renaissance technologies llc | 979,300 | $4.5M |
| morgan stanley | 618,327 | $2.9M |
| schroder investment management group | 615,833 | $2.7M |
| diadema partners lp | 476,424 | $2.2M |
| birchview capital, lp | 463,599 | $2.2M |
| silvercrest asset management group llc | 428,684 | $2.0M |
Showing top 10 of 94 institutional holders of BICYCLE THERAPEUTICS PLC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BICYCLE THERAPEUTICS PLC's pipeline?
BICYCLE THERAPEUTICS PLC (BCYC) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BICYCLE THERAPEUTICS PLC's lead drug candidate?
BICYCLE THERAPEUTICS PLC's most advanced tracked candidate is bt1702 (Preclinical) for oncology.
What is BICYCLE THERAPEUTICS PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BICYCLE THERAPEUTICS PLC has approximately 26.3 months of cash runway.
What is BICYCLE THERAPEUTICS PLC's market capitalization?
BICYCLE THERAPEUTICS PLC's market capitalization is approximately $282.7M.
Who is the CEO of BICYCLE THERAPEUTICS PLC?
Dr. Kevin Lee M.B.A., Ph.D. is the chief executive officer of BICYCLE THERAPEUTICS PLC (BCYC).
Get the full picture on BICYCLE THERAPEUTICS PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.